Stockscreener 앱 받기
170.72
0.35%
0.59
시간 외 거래:
170.72
전일 마감가:
$170.13
열려 있는:
$170.22
하루 거래량:
531.28K
Relative Volume:
0.58
시가총액:
$8.40B
수익:
$4.06B
순이익/손실:
$413.08M
주가수익비율:
21.31
EPS:
8.01
순현금흐름:
$560.48M
1주 성능:
-1.59%
1개월 성능:
+12.14%
6개월 성능:
+61.18%
1년 성능:
-11.94%
1일 변동 폭
$168.71
$173.02
1주일 범위
$166.86
$174.73
52주 변동 폭
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
CRL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
170.72 | 8.37B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
527.87 | 198.56B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
206.10 | 147.61B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
639.15 | 50.96B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
139.65 | 39.13B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
203.12 | 34.81B | 15.70B | 1.24B | 2.01B | 6.9036 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-06 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-05-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Charles River Labs forms Scientific Advisory Board to advance NAMs By Investing.com - Investing.com Nigeria
Charles River Labs taps former FDA leader to help move away from animal tests - The Business Journals
Key resistance and support levels for Charles River Laboratories International Inc.July 2025 Recap & Reliable Entry Point Trade Alerts - newser.com
Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoptio - PharmiWeb.com
Fairjourney Biologics acquires Charles River Laboratories South San Francisco facility - MSN
Charles River Labs forms Scientific Advisory Board to advance NAMs - Investing.com India
Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoption - Business Wire
Can you recover from losses in Charles River Laboratories International Inc.July 2025 Closing Moves & Fast Gain Stock Trading Tips - newser.com
Why Charles River Laboratories International Inc. stock is seen as undervalued2025 Technical Overview & Fast Momentum Stock Entry Tips - newser.com
What does recent volatility data suggest for Charles River Laboratories International Inc.Weekly Investment Recap & Verified Stock Trade Ideas - newser.com
Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call - BioSpace
A Look at Charles River Laboratories' Valuation Following Strategic ReproTracker Partnership with Toxys - simplywall.st
How to integrate Charles River Laboratories International Inc. into portfolio analysis toolsJuly 2025 Final Week & Growth-Oriented Investment Plans - newser.com
Why hedge funds are buying Charles River Laboratories International Inc. stockJuly 2025 Analyst Calls & Long-Term Growth Stock Strategies - newser.com
Will Charles River Laboratories International Inc. (RV6) stock sustain uptrend momentumJuly 2025 Review & Technical Pattern Recognition Alerts - newser.com
Will Charles River Laboratories International Inc. bounce back from current supportQuarterly Profit Review & Target Return Focused Stock Picks - newser.com
Tick level data insight on Charles River Laboratories International Inc. volatilityEntry Point & Real-Time Buy Signal Alerts - newser.com
Understanding Charles River Laboratories International Inc.’s price movement2025 Technical Patterns & Risk Managed Investment Signals - newser.com
TD Cowen Adjusts Price Target on Charles River Laboratories International to $205 From $179, Maintains Buy Rating - MarketScreener
Charles River Laboratories (CRL): Investor Outlook Reveals Potential 8.68% Upside - DirectorsTalk Interviews
Allspring Global Investments Holdings LLC Acquires 516,521 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International, Inc. $CRL Shares Sold by Truist Financial Corp - MarketBeat
Could Charles River (CRL) Redefine Its Competitive Edge with New Non-Animal Toxicology Platform? - simplywall.st
Charles River Laboratories International, Inc. $CRL Shares Sold by Lawson Kroeker Investment Management Inc. NE - MarketBeat
Janney Montgomery Scott LLC Has $1.58 Million Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Labs (CRL): Examining Valuation Following Recent Share Price Rebound - Yahoo Finance
Charles River Laboratories International Inc. Stock Underperforms Friday When Compared To Competitors - 富途牛牛
Why Charles River Laboratories International Inc. (RV6) stock is trending on social mediaGlobal Markets & Community Trade Idea Sharing Platform - newser.com
Published on: 2025-10-10 13:12:55 - newser.com
Can Charles River Laboratories International Inc. stock deliver strong Q4 earningsWeekly Risk Report & AI Powered Buy and Sell Recommendations - newser.com
Weiss Ratings Reiterates "Sell (D)" Rating for Charles River Laboratories International (NYSE:CRL) - MarketBeat
Charles River Laboratories International Inc. stock prediction for this weekCPI Data & Expert Approved Momentum Ideas - newser.com
Published on: 2025-10-09 06:30:08 - newser.com
Does Charles River Laboratories International Inc. (RV6) stock trade below intrinsic valueQuarterly Earnings Summary & Real-Time Volume Analysis - newser.com
Is Charles River Laboratories International Inc. (RV6) stock positioned for digital growth eraInsider Buying & Stock Portfolio Risk Control - newser.com
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing - BioSpace
Winners And Losers Of Q2: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Drug Development Inputs & Services Stocks - Yahoo Finance
What drives Charles River Laboratories International Inc stock priceMorning Star Patterns & High Yield Portfolio Picks - earlytimes.in
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicit - PharmiWeb.com
Charles River, Toxys Form Partnership on Use of Drug Toxicity Detection Tool - MarketScreener
Charles River (CRL) Partners with Toxys to Enhance Toxicity Testing - GuruFocus
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.22%
1.06%
자본화:
|
볼륨(24시간):